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Five year follow-up in patients with completely resected stage I 
non-small cell lung cancer following adjuvant chemotherapy with 
UFT
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1 Yongdong Severance Hospital, Yonsei University College of Medicine, 
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Background: Adjuvant treatment following curative resection in stage 
I NSCLC has some controversies, and only a few randomized studies 
have been reported advocating adjuvant UFT chemotherapy for early-
stage NSCLC patients. The purpose of this study was to evaluate the ef-
ﬁcacy of adjuvant UFT chemotherapy in pathological stage I NSCLC.
Methods: We retrospectively studied 86 stage I NSCLC patients who 
underwent complete surgical resection between July 1996 and March 
2002. The patients were randomly assigned to UFT group (n=47, 
surgery and UFT chemotherapy) or control group (n=39, surgery 
alone). Two grams of UFT was administered daily in UFT group for 
21.3±11.7(mean±SD) months.
Results: There were 65 males and 21 females. Mean age at surgery 
was 61.1±10.8 years. Overall mean survival time was 64.9±26.5 
months. Administration of UFT was stopped in 8 patients (17.0%) 
within 12 months due to recurrence in 3 patients, self withdrawal in 3 
patients, and due to severe nausea and poor oral intake in 2 patients. 
The overall 5-year survival rates were 71.9% for the UFT group and 
73.0% for the control group, with no statistically signiﬁcant differ-
ence (p=0.90). In adenocarcinoma patients (N=45), the 5-year survival 
rates were 76.6% for the UFT group (N=26) and 77.1% for the control 
group (N=19), with no statistically signiﬁcant difference (p=0.99). For 
non-adenocarcinoma patients (N=41), the 5-year survival rates were 
66.3% for the UFT group (N=21) and 69.3% for the control group 
(N=20), with no statistically signiﬁcant difference (p=0.82). For stage 
T1 patients (N=36), the 5-year survival rates were 78.3% for the UFT 
group (N=19) and 81.3% for the control group (N=17) with no statisti-
cally signiﬁcant difference (p=0.72). For stage T2 patients (N=50), 
the 5-year survival rates were 67.5% for the UFT group (N=28) and 
67.1% for the control group (N=22), with no statistically signiﬁcant 
difference (p=0.91). The 5-year disease-free survival rates were 65.0% 
for the UFT group and 68.5% for the control group, and there was also 
no statistically signiﬁcant difference (p=0.22). Complications such as 
nausea, general weakness and poor oral intake were noted in 4 patients 
(8.5%) in UFT group.
Conclusions: UFT adjuvant chemotherapy did not increase survival in 
patients with pathologic stage I NSCLC, and prospective randomized 
trial should be applied in the future to draw to a ﬁnal conclusions.
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Prognostic factors in patients with stage IV non-small-cell lung 
cancer
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Bo; Yu, Yongfeng; Pei, Jun; Zhang, Wei 
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Objective: To study incidence of metastasis of stage IV non-small cell 
lung cancer, and analysis prognostic and metastasis organs in non-small 
cell lung cancer (NSCLC) 
Methods: 313 patients with stage IV in NSCLC entered this study 
from 1999.1~2005.4 Three types of data were collected: (1) clinical 
features: generalized status (include sex, age, Kps, typing, pathological 
typing, smoking history, appetite, weight ect): TNM stage (T stage, N 
stage, metastasis).(2) laboratory measurements: HB, LDH, AKP, AST, 
ALT, BUN, CR, albumin: serum tumor marker (CEA, CYFRA211, 
NSE).(3) therapy measure: chemotherapy, the cycle of chemotherapy, 
program, cranial irradiation, bone irradiation, phosphate therapy act. 
Median survival time, overall survival rate, distant metastasis rate were 
the endpoints. Kaplan-Meier method was used for university analysis 
and Cox proportional hazard regression model was used for multivari-
ate analysis. 
Results: 218 and 95 patients metastases to single and different organ 
among the 313 cases of non-small cell (NSCLC) at stage IV. There 
were 63, 174, 127, 3 6, 18, 11, 5 patients with metastasis respectively to 
brain, bone, liver, adrenal gland, subcutaneous and others. The overall 
median survival time for all 313 cases of NSCLC patients was 10.8 
(9.00-12.30) months and the overall 1-,2-,3-,4-and 5-year survival rates 
were 45%, 18%, 12%, 4%, 0%. Kaplan-Meier estimate showed that 
patients anatomic typing, Kps, numbers of metastasis organ, appetite, 
liver, adrenal gland and subcutaneous metastasis, body weight loss, 
smoking, index of smoking, chemotherapy, cycles of chemotherapy 
were the predictors of survival. Multivariate analysis showed statisti-
cally signiﬁcant correlation with anatomic typing, Kps, appetite, liver 
and subcutaneous metastasis, body weight loss, cycles of chemother-
apy. The relative risk (RR) was 1.51, 1.97, 1.55, 1.67, 2.56, and 2.56 
respectively. 
Conclusion: The overall median survival time for all 313 cases of 
NSCLC patients was 10.8 (9.00-12.30) months and the overall 1-,2-
,3-,4-and 5-year survival rates were 45%, 18%, 12%, 4% and 0%. 
Survival time distinctly decreased in patients who had distant metasta-
sis more than two different organs (P<0.01= the median survival time 
was 7.1 months. Bone was the commonest organ to metastatic. The in-
cidence of distant metastasis respectively was 55.59% with bone metas-
tasis 40.58% with lung metastasis 0.13% with brain metastasis 11.50% 
with liver metastasis 5.75% with adrenal gland metastasis, 3.51% with 
subcutaneous metastasis. The survival time was shortest in subcutane-
ous metastasis (4.6 months), and one after another liver 7.0 months, 
brain 8.0 months,adrenal gland 8.6 months, bone 10.6 months, lung 
11.8 months. Cox Multivariate analysis showed liver and subcutaneous 
metastasis, anatomic typing, Kps, appetite, body weight loss, cycles of 
chemotherapy were independent prognostic factors in patient with stage 
IV non-small cell lung cancer.
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Multivariate analysis of factors predictive of brain metastases in 
352 patients with non-small cell lung carcinoma
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Objective: This retrospective study attempts to determine the prognos-
tic factors of lung cancer patients with brain metastases and to analysis 
the impact of multi-treatment modalities over survival. We also try 
to investigate the relationship between the expression of P53, nm23, 
VEGF in cancer tissues and the survival of these patients. 
Methods: We reviewed the clinical characteristics of 252 lung cancer 
patients with brain metastases. The multivariate analysis was per-
formed with Cox’s proportion risk model. Treatment modalities include 
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palliative therapy, simple WBRT or simple chemotherapy, combined 
radiochemotherapy, stereotactic linac-based radiosurgery plus che-
motherapy/ WBRT and neurosurgical resection plus chemotherapy/ 
WBRT. Ninety-two specimens of lung cancer were examined for P53, 
nm23 and VEGF by immunohistochemical staining. Survival analysis 
was compared with Kaplan-Meier method and log-rank test was used 
respectively. Statistical signiﬁcance was deﬁned as P<0.05. 
Results: The univariate analysis showed that performance status, age, 
the number of brain metastases, the absence or presence of extracranial 
metastases and metastatic symptoms had inﬂuences over survival pe-
riod. The multivariate analysis showed that performance status, age and 
the absence or presence of extracranial metastases were related to prog-
nosis. The median survival time of patients receiving palliative therapy, 
simple WBRT or simple chemotherapy, combined radiochemotherapy, 
stereotactic linac-based radiosurgery plus chemotherapy/ WBRT and 
neurosurgical resection plus chemotherapy/ WBRT was 1.7 months, 
3.2 months, 9.0 months, 10.6 months and 17.1 months respectively. 
The median survival time of patients with P53(+)/P53(-), nm23(+)/(-) 
and VEGF(+)/(-)was 11.7/10.6months (P=0.5179), 12.8/9.9 months 
(P=0.1075) and 10.6 /12.0 months (P=0.0231) respectively. 
Conclusions: Performance status, age and the absence or presence of 
extracranial metastases are the independent prognostic factors. The 
patients with PS score 0~1, age< 60 years and the absence of extracra-
nial metastases have longer survival time and they would beneﬁt from 
aggressive treatment modalities. Either combined radiochemotherapy 
or stereotactic linac-based radiosurgery plus chemotherapy/ WBRT 
is effective. There is a longer survival tendency in patients receiving 
stereotactic linac-based radiosurgery plus chemotherapy/ WBRT. The 
expression of VEGF is related to the survival of the patients while 
the expression of P53 and nm23 is unrelated to the survival time. The 
patients with VEGF positive expression have shorter survival time.
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Feasibility of sleeve lobectomy with induction chemoradiotherapy: 
Analysis of morbidity and recurrence pattern compared with sleeve 
lobectomy without induction therapy
Hirami, Yuji; Date, Hiroshi; Tao, Hiroyuki; Yamane, Masaomi; 
Toyooka, Shinichi; Aoe, Motoi; Sano, Yoshifumi 
Dept. of Cancer and Thoracic Surgery, Graduate School of Medicine, 
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Japan
Purpose: The purpose of this study was to evaluate the feasibility of 
sleeve lobectomy after induction chemoradiotherapy.
Methods: We reviewed seven patients who underwent sleeve lobec-
tomy after inductin chemoradiotherapy(Group A) for locally advanced 
non-small cell lung cancer, and 19 patients who underwent sleeve 
lobectomy without induction therapy(Group B). 
Results: The complication of group A was in 3 (33%) of 7 cases, 1 
necrosis of apex of lower lobe, 1 atelectasis and 1 arrhythmia. Of 
group B was in 9(47%) of 19 cases, 2 failure of anastomosis, 3 air 
leakage>7day, 3 wound infection, 2 arrhythmia, 2 recurrent nerve palsy, 
and 1 pneumonia. The recurrence of group A was in 2(29%) of 7 cases. 
One case was brain on the 220th and pulmonary on the 430th. Another 
one case was kidney on the 365th and duodenum on the 700th. The 
recurrence of group B was in 3(16%) of 19 cases, which were observed 
in 1 pulmonary, 1 skin, and 1 plural, respectively.
Conclusions: The complication of bronchial anastomosis and local 
recurrence was not permitted in group A. Although it is a small number 
of study, sleeve lobectomy with induction chemoradiotherapy is con-
sidered to be feasible technique from safety and oncologically.
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Gemcitabine weekly as a radiosensitiser for the treatment of brain 
metastases in patients with non-small cell lung cancer: a phase I 
study
Huang, Yujuan; Wu, Yilong; Xie, Songxi; Yang, Jing-Ji; Huang, Yi-
Sheng; Lioa, Ri-Qiang 
Lung Cancer Institute of Guangdong Provincial People’s Hospital, 
Guangzhou, China
Background: Conventional treatment for non-small cell lung cancer 
(NSCLC) brain metastases (BM) is whole-brain radiotherapy (WBRT). 
The efﬁcacy is limited. It might be increased by a potent radiosen-
sitiser such as gemcitabine, which is believed to cross the disrupted 
blood–brain barrier. Primary objective of this study was to determine 
the maximum tolerated dose (MTD) of weekly gemcitabine given 
concurrently with WBRT. 
Methods: Patients with BM from NSCLC were included. The dose of 
WBRT was 3750 cGy (total 15 times, 3 weeks). Gemcitabine was given 
concurrent with WBRT on days 1 and 8 and 15. Starting dose was 400 
mg/m2, escalated by 100 mg/m2 increments. At least three patients were 
included per level. Dose limiting toxicity (DLT) was deﬁned as grade 
4 hematological or grade 2 neurological toxicity. When two or more 
patients experience DLT, the MTD was reached. 
Results: A total of 16 patients were included; 69% had a PS 1. A total 
of 69% had concurrent active extra cranial diseases. All had more than 
3 BM. Up to 600 mg/m2 (level 3) no neurology toxicity was observed. 
At 600 mg/m2, two out of 6 patients developed grade 4 thrombocyto-
penia. One of the two patients’ thrombocytopenia was confused with 
disseminated intravascular coagulation (DIC). At 700 mg/m2, two out 
of 4 patients developed neurotoxicities. One developed grade 3 seizure 
and confusion. Another patient developed suspected grade 2 muscle 
weakness(neuropathy motor). 
Conclusions: The MTD was reached at dose 700 mg/m2. The dose of 
600 mg/m2 would be considered for further study. 
This study was supported by the China Society Clinical of Oncology 
foundation (No.Y-2005--0010) 
P2-184 NSCLC: Combined Modality Therapy Posters, Tue, Sept 4 
Safety study of induction chemotherapy followed by Synchronous 
Radiotherapy (RT) and cetuximab in stage III non-small cell lung 
cancer (NSCLC): SCRATCH study (Cohort I)
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